Herombopag Promotes Platelet Engraftment and Decreases Platelet Transfusion After Allogeneic Hematopoietic Stem Cell Transplantation.

The delayed platelet engraftment associated with allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a common complication and often results in increased transplant-related complications. A single-center, prospective, investigator-initiated pilot study was conducted to explore whether herombopag, a 2nd generation thrombopoietin-receptor agonist, would promote platelet engraftment after allo-HSCT. Between 2/2022 and 06/2022, seventeen individuals (median age 39; range 15-58 years) with hematological malignancies were enrolled. Herombopag was given for a median of 22 (range 14-61) days at a dose of 7.5 mg/d. The median time to neutrophil >500/μl was 11 (range 9-19) days. The median time to platelet >20,000/μl and >50,000/μl was 13 (range 8-22), and 20 (range 14-45) days, respectively. Compared with historical controls, the cumulative incidence of platelet engraftment after HSCT was significantly higher in the herombopag group (>20,000/μl at day +21, 88% vs 65%, p=0.003; >50,000/μl at day +30, 65% vs 43%, p=0.001). Herombopag also reduced the units of platelet transfusion within 30 days post-SCT (3.6±2.5 vs 5.4±3.2 U, p=0.01). In conclusion, it seems likely that herombopag could enhance platelet engraftment after allo-HSCT.